- Home
- NXG vs DERM Comparison
NXG vs DERM Comparison
Compare NXG & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXG
- DERM
- Stock Information
- Founded
- NXG 2012
- DERM 2014
- Country
- NXG United States
- DERM United States
- Employees
- NXG N/A
- DERM N/A
- Industry
- NXG
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- NXG
- DERM Health Care
- Exchange
- NXG Nasdaq
- DERM Nasdaq
- Market Cap
- NXG 170.5M
- DERM 181.0M
- IPO Year
- NXG N/A
- DERM 2021
- Fundamental
- Price
- NXG $47.13
- DERM $8.06
- Analyst Decision
- NXG
- DERM Strong Buy
- Analyst Count
- NXG 0
- DERM 2
- Target Price
- NXG N/A
- DERM $10.00
- AVG Volume (30 Days)
- NXG 24.4K
- DERM 103.3K
- Earning Date
- NXG 01-01-0001
- DERM 05-14-2025
- Dividend Yield
- NXG 14.78%
- DERM N/A
- EPS Growth
- NXG N/A
- DERM N/A
- EPS
- NXG N/A
- DERM N/A
- Revenue
- NXG N/A
- DERM $56,243,000.00
- Revenue This Year
- NXG N/A
- DERM $29.83
- Revenue Next Year
- NXG N/A
- DERM $54.88
- P/E Ratio
- NXG N/A
- DERM N/A
- Revenue Growth
- NXG N/A
- DERM N/A
- 52 Week Low
- NXG $30.32
- DERM $3.54
- 52 Week High
- NXG $42.29
- DERM $8.24
- Technical
- Relative Strength Index (RSI)
- NXG 54.51
- DERM 63.48
- Support Level
- NXG $46.50
- DERM $6.55
- Resistance Level
- NXG $47.26
- DERM $7.00
- Average True Range (ATR)
- NXG 0.87
- DERM 0.64
- MACD
- NXG -0.09
- DERM 0.12
- Stochastic Oscillator
- NXG 42.17
- DERM 87.02
About NXG NXG NextGen Infrastructure Income Fund of Beneficial Interest
Cushing NextGen Infrastructure Income Fund is a closed-end investment management company. Its investment objective is to seek a high total return with a focus on current income. The Fund invests at least 80% of its net assets in a portfolio of equity and debt securities of infrastructure companies, including energy infrastructure companies, industrial infrastructure companies, sustainable infrastructure companies, and technology & communication infrastructure companies.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.